US · LLY
Eli Lilly and Company
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Indianapolis, IN 46285
- Website
- lilly.com
Price · as of 2025-12-31
$963.33
Market cap 992.6B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $617.75 | -35.87% |
| Intrinsic Value(DCF) | $1,330.72 | +38.14% |
| Graham-Dodd Method(GD) | $47.96 | -95.02% |
| Graham Formula(GF) | $1,171.71 | +21.63% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $29.24 | $61.44 | $31.22 | $1.03 | $51.15 |
| 2012 | $42.54 | $55.37 | $9.68 | $0.78 | $5.12 |
| 2013 | $46.87 | $60.32 | $10.15 | $6.92 | $42.93 |
| 2014 | $57.65 | $47.29 | $8.76 | $0.00 | $0.00 |
| 2015 | $63.21 | $54.25 | $5.86 | $0.00 | $21.47 |
| 2016 | $73.33 | $60.64 | $8.13 | $0.00 | $35.44 |
| 2017 | $71.06 | $56.46 | $9.56 | $0.00 | $0.00 |
| 2018 | $115.70 | $96.15 | $15.55 | $0.00 | $48.43 |
| 2019 | $132.07 | $103.89 | $10.93 | $4.57 | $102.21 |
| 2020 | $197.96 | $132.33 | $56.81 | $0.00 | $114.58 |
| 2021 | $257.18 | $148.78 | $109.59 | $0.00 | $133.80 |
| 2022 | $308.11 | $172.44 | $83.43 | $0.00 | $58.46 |
| 2023 | $751.65 | $381.42 | $186.93 | $0.00 | $156.61 |
| 2024 | $863.19 | $493.02 | $433.80 | $0.00 | $455.52 |
| 2025 | $1,017.97 | $617.75 | $1,181.34 | $47.96 | $1,171.71 |
AI valuation
Our deep-learning model estimates Eli Lilly and Company's (LLY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $617.75
- Current price
- $963.33
- AI upside
- -35.87%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1,330.72
+38.14% upside
Graham-Dodd
$47.96
-95.02% upside
Graham Formula
$1,171.71
+21.63% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LLY | Eli Lilly and Company | $963.33 | 992.6B | -36% | +38% | -95% | +22% | 44.29 | 34.45 | 14.03 | 33.98 | 46.14 | 64.76 | 83.79% | 45.56% | 31.66% | 101.36% | 44.87% | 21.59% | 1.60 | 37.34 | 1.58 | 0.78 | 1.27 | 9599.00% | 4470.00% | 206558.00% | 0.98% | 0.48 | 16.90% | 0.59% | 26.10% | 1.04% | 31.97 | 105.82 | 14.57 | 8.36 |
| ABBV | AbbVie Inc. | $232.03 | 410.27B | -31% | -54% | — | -83% | 99.26 | -128.28 | 6.86 | 17.08 | — | -4.58 | 83.71% | 34.69% | 6.91% | 15367.27% | 21.58% | 3.14% | -21.12 | 8.08 | 0.67 | 0.41 | 2.26 | -126.00% | 857.00% | -9.00% | 4.25% | 0.44 | 28.25% | 2.78% | 275.80% | 3.01% | 22.78 | 27.13 | 7.90 | 2.52 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| AZN | AstraZeneca PLC | $208.45 | 646.31B | -44% | -57% | -100% | -74% | 61.77 | 12.98 | 10.75 | 33.06 | 32.62 | -60.60 | 81.90% | 23.40% | 17.46% | 22.86% | 16.43% | 9.38% | 0.61 | 8.11 | 0.94 | 0.68 | 1.21 | 18938.00% | 863.00% | 6172.00% | 1.86% | 0.48 | 17.05% | 0.80% | 49.70% | 1.02% | 47.70 | 55.72 | 11.16 | 6.83 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| JNJ | Johnson & Johnson | $248.43 | 598.69B | -22% | -48% | — | -38% | 22.52 | 7.40 | 6.41 | 15.83 | 24.88 | -34.24 | 72.78% | 27.17% | 28.46% | 35.03% | 21.82% | 14.13% | 0.59 | 26.36 | 1.03 | 0.69 | 0.71 | 9050.00% | 605.00% | -73.00% | 3.26% | 0.45 | 20.41% | 2.05% | 46.20% | 3.04% | 24.67 | 32.06 | 6.70 | 5.17 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| NVO | Novo Nordisk A/S | $37.45 | 166.46B | +59% | +7% | — | -3% | 10.46 | 5.52 | 3.60 | 8.17 | 591.70 | 16.74 | 80.34% | 43.69% | 33.14% | 60.70% | 39.34% | 20.31% | 0.67 | 19.92 | 0.80 | 0.48 | 0.73 | 177.00% | 234.00% | -5838.00% | 2.71% | 0.55 | 11.19% | 4.65% | 48.60% | 4.77% | 9.05 | 40.54 | 3.95 | 3.59 |
| NVS | Novartis AG | $168.62 | 325.95B | -29% | -50% | — | -40% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- CEO
- David A. Ricks
- Employees
- 47K
- Beta
- 0.39
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1,330.72 ÷ $963.33) − 1 = +38.14% (DCF, example).